Grail Files For $100M IPO, Plans To Launch Multi-Cancer Early Detection Test In 2021
Grail hopes to launch its Galleri test in 2021 as a laboratory developed test and submit a PMA to the US FDA in 2023.
You may also be interested in...
The company launched the lab test in the US. New results from PATHFINDER trial showed an earlier version of Galleri can detect many types of cancer, including early-stage cancer that has yet to metastasize.
Illumina announced plans to acquire Grail for about $8bn in September 2020, but the US FTC says the proposed acquisition will diminish innovation in the US market for multi-cancer testing.
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the first day of the meeting.